drugset / Trial / NCT05336786

Prostate Cancer Diagnosis by Multiparametric Ultrasound (Wholemount)

NCT05336786

NaSingle-groupOpen-labelDiagnostic

Summary

This phase III trial investigates if perflutren lipid microspheres with ultrasound can be used to diagnose prostate cancer non-invasively. Definity (perflutren lipid microspheres) is an ultrasound contrast agent that is typically used for ultrasound bubble studies that involve the heart. Definity appears on ultrasound images as tiny gas-filled microbubbles. These microbubbles are about the size of a red blood cell and do not stay in a patient's body for more than several minutes, where they are excreted from the lungs and exhaled back into the air when breathing. Definity may enhance ultrasound images of the prostate and help doctors identify prostate cancer on ultrasound images.

Timeline

Start
2022-06-15
Primary completion
2025-05-26
Completion
2026-05-26

Drugs

EvaluationDrugModalityDoseRoute
Subject Definity Diagnostic / imaging agent Intravenous

Indications